Adams Catherine Owen - 23 Sep 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Chief Executive Officer, Director
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
23 Sep 2024
Net transactions value
$0
Form type
4
Filing time
25 Sep 2024, 18:53:04 UTC
Previous filing
24 Jun 2024
Next filing
26 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Award $0 +353,261 $0.000000 353,261 23 Sep 2024 Common Stock 353,261 $16.29 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Stock Option has been granted pursuant to the Issuer's 2024 Inducement Plan as a material inducement to the reporting person's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
F2 25% of the shares subject to the Stock Option will vest and become exercisable on September 23, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.